Blitz Briefing - Asia Pac Digital Therapeutics Landscape We explore the following areas: - What are some the promising DTx startups in Asia building? - What therapeutics areas are the focus of DTx in the region? - Why is DTx of increasing importance to pharmacos, insurers and other verticals? - What is the right business model for a DTx startup in Asia?

1. ©2019 by Galen Growth Asia - All rights reserved.
1
DTX WEBINAR ONLY | NOT FOR DISTRIBUTION
BLITZ BRIEFINGS
DIGITAL THERAPEUTICS
IN
ASIA PACIFIC

2. ©2019 by Galen Growth Asia - All rights reserved.
2
DTX WEBINAR ONLY | NOT FOR DISTRIBUTION
DIGITAL THERAPEUTICS ARE COMING OF AGE
• DTx solutions will increasingly influence the way healthcare is delivered
and consumed across Asia
• DTx is a distinct category within the now broad HealthTech, aka digital
health, taxonomy
• DTx represents an significant opportunity to address disease areas that
are poorly served in Asia today
• DTx is also an opportunity to address the affordability challenge which
exist in developing Asia
• Obstacles stand in the way of this promising category making a positive
impact on health outcomes
Role in healthcare
• Provide patients, providers and payers with novel treatment options for
unmet medical needs
• Be used independently or in conjunction with other treatment options
• Enhance and support current medical treatments
• Reduce reliance on certain pharmaceutical or other treatments
• Integrate into medical guidelines and best practices
Solution Classifications
• Address a medical condition
• Manage or prevent a medical disorder or disease
• Optimise medication/Rx
• Treat a medical disease or disorder
Digital therapeutics (DTx) are evidence-based therapeutic interventions enabled by data and cognitive computing to
prevent, manage, or treat a medical disorder or disease

3. ©2019 by Galen Growth Asia - All rights reserved.
3
DTX WEBINAR ONLY | NOT FOR DISTRIBUTION
Health Services
Search
ResearchHealth Management
Solutions
Medical EducationTelemedicine
Online Marketplace
Wellness
Medical Diagnostics
Patient Solutions Remote MonitoringOnline Health
Communities
Payments & Insurance VeterinarianPopulation Health
Management
Medical Concierge
Medical Tourism
Drug Discovery
Next Generation Sequencing
Genomics Related Research
Clinical Trials
EHR / EMR
Physician / Clinic
Hospital
Pharmacy
HCP Education
Health Information Platform
Consumer Education
Teleconsultation
Consumer Marketplace
Professional Marketplace
On-demand Lab Tests
Wellness Apps
Wearables
Smart Equipment
Wellness Information Platform
Genomics Related Applications
Wellness Screens
Medical Imaging
Diagnosis Tools
Liquid Biopsy
Digital Therapeutics
Patient Self-Diagnosis
Disease Management
Home Healthcare
Remote Monitoring
Devices
Patient Health Forums
Physician Networks
Other HCP Networks
Health Claim Management
Medical Payments
Health ForumsCorporate Health
Integrated Solutions
Others
Social Enterprise
HCP Job Board
Software Provider
Contamination Management
DTX IS A HEALTHTECH CATEGORY

4. ©2019 by Galen Growth Asia - All rights reserved.
4
DTX WEBINAR ONLY | NOT FOR DISTRIBUTION
NOT EVERY APP OR TECHNOLOGY IS A DIGITAL THERAPEUTIC
Replacement Therapy
• Treatment which potentially could replace traditional pharmaceutical
and medical device products
Digital companions and replacement therapies are the two distinct segments emerging in the fast developing field of digital
therapeutics
Digital Companion
• Treatment solution which extend the value of traditional
pharmaceutical products, through a companion app providing:
• Adherence management
• Personalised treatment recommendations
Example
• Akili Interactive is building clinically validated treatments for
neurological and psychiatric conditions to be deployed on personal
devices e.g. iPad
• It is app-based, algo powered sensory stimulus delivered through an
action video game interface on a device
• Potentially a primary treatment for ADHD, depression, Alzheimer’s
disease and traumatic brain injury, reducing or elimination the need
for pharmaceutical of f2f therapy
• Awaiting an FDA clearance decision on its recently filed digital
therapeutic for paediatric ADHD
Example
• Susmed provides software solutions to support the
treatment of insomnia in patients
• The software is protected under 8 international patents
and is currently in the 3rd clinical phase, set for
completion in 2020
• Further details on slide 8

5. ©2019 by Galen Growth Asia - All rights reserved.
5
DTX WEBINAR ONLY | NOT FOR DISTRIBUTION
ASIA PAC DIGITAL THERAPEUTICS LANDSCAPE
• Therapeutic areas of greater focus include:
• Diabetes
• Cardiovascular Diseases
• Mental Health
• Respiratory Diseases
• Other chronic diseases
Not exhaustive
$74
$172
(YTD)
2018
2019
19 17 (YTD)Investment Volume
Investment Value
Only 7% of the Asia digital health ecosystem can be categorized as a digital therapeutic, which is constraining deal volume
and not deterring investors

6. ©2019 by Galen Growth Asia - All rights reserved.
6
DTX WEBINAR ONLY | NOT FOR DISTRIBUTION
OBSTACLES TO REALISING THE PROMISE
• Regulations
• Greater clarity is required from Asia’s regulators:
• FDA is setting a precedence with the approval of reSET-O (Pear Therapeutics) in late 2018
• Pharmacos benefit from up to 20 years of patent protection on novel drugs, why not DTx?
• Evidence
• Clinical Trials
• Independent, one or more multi-center, randomized, controlled trials
• Health economic outcomes
• Real World Evidence: ongoing clinical research in the target population
• Adoption
• HCPs will need to become greater advocates and prescribers of DTx solutions
• Assumption is that both clinical evidence and regulations will reduce their reticence
• Patients will also need to shift paradigm
• Biz Model
• Sustainably profitable
• Affordable to both patients in mature and developing markets
• Insurers will need to play a greater role
The opportunity for DTx to address important health conditions is a no brainer, but the pathway towards widespread
adoption will be onerous and likely to be a long timeline

7. ©2019 by Galen Growth Asia - All rights reserved.
7
DTX WEBINAR ONLY | NOT FOR DISTRIBUTION
ASIA
DTX
SOLUTIONS

8. ©2019 by Galen Growth Asia - All rights reserved.
8
DTX WEBINAR ONLY | NOT FOR DISTRIBUTION
Research
Awareness
Diagnosis
Treatment
Management
W
orkflow
Prevention
HEALTHTECH
CATEGORY
HEALTHVALUE
PROPOSITIONTECHNOLOGIES
• Susmed provides software solutions to support the treatment of
insomnia in patients.
• The software is protected under 8 international patents and is currently
in the 3rd clinical phase, set for completion in 2020.
• Susmed also uses blockchain technology for data security and data
privacy.
Susmed
DESCRIPTION
• Software solution for patients treatment
• Blockchain based system for clinical development
PRODUCT DESCRIPTION
INVESTMENT HISTORY
HEALTHTECH CATEGORISATION & CLASSIFICATION
TOKYO, JAPAN
MANAGEMENT
HEALTHTECH ALPHA ASSESSMENT
RELATIONSHIPSDIGITAL THERAPEUTICS
• Blockchain
• Machine Learning / Deep Learning
Date Investors Stage Amount
12 / 2016 Beyond Next Ventures Seed $0.20M
02 / 2017 Beyond Next Ventures Series A $0.91M
03 / 2018 Beyond Next Ventures, SBI
Investment
Series B $5.43M
06 / 2018 Sony, Tokyo Century, M3 Series B1 $1.40M
Name / Title Background
Taro Ueno (CEO)
M.D., Ph.D. Entrepreneur experienced in healthcare,
innovation and venture capital
Daisuke Ichikawa (COO) M.D., Ph.D. Machine learning for clinical data.
Tomomitsu Motohashi
(CTO)
Machine Learning. 2nd prize at KDD cup 2015
+10
+15
-5 +7
+17
-20
0
20
Alpha
M
om
entum
M
arket
Im
pact
M
oney
Alpha Indices relative to the average value for each index in Japan

9. ©2019 by Galen Growth Asia - All rights reserved.
9
DTX WEBINAR ONLY | NOT FOR DISTRIBUTION
Research
Awareness
Diagnosis
Treatment
Management
W
orkflow
Prevention
HEALTHTECH
CATEGORY
HEALTHVALUE
PROPOSITIONTECHNOLOGIES
• Perx helps health organisations drive patient engagement and treatment
adherence in the most positive, effective and rewarding way and in
doing so reduce health care costs and improve patient lives. Best of all
patients love the experience of simple, rewarding healthcare.
Perx Health
DESCRIPTION
• Our smartphone-based programs leverage proven behavioural science
and consumer tactics to help every patient change their behaviour and
so achieve better outcomes. Our technology is flexible for patients,
therapeutic areas and clinical contexts and is supported by clinical and
business tools.
PRODUCT DESCRIPTION
INVESTMENT HISTORY
HEALTHTECH CATEGORISATION & CLASSIFICATION
SYDNEY, AUSTRALIA
MANAGEMENT
HEALTHTECH ALPHA ASSESSMENT
RELATIONSHIPSDIGITAL THERAPEUTICS
• Mobile Application
• Machine Learning / Deep Learning
• Web-based clinical and business tools
+5
-11
+15
+6
-11
-20
0
20
Alpha
M
om
entum
M
arket
Im
pact
M
oney
Alpha Indices relative to the average value for each index in Australia
Name / Title Background
Hugo Rourke Ex-McKinsey with specialization in loyalty and gaming
Scott Taylor Ex-Finance with technology investment background
Will Delaat Ex-MD of Merck Aus., Ex-Chair of Medicines Aus.
Date Investors Stage Amount
12 / 2017
Giant Leap Fund, Artesian
VC
Seed undisclosed

10. ©2019 by Galen Growth Asia - All rights reserved.
10
DTX WEBINAR ONLY | NOT FOR DISTRIBUTION
Research
Awareness
Diagnosis
Treatment
Management
W
orkflow
Prevention
HEALTHTECH
CATEGORY
HEALTHVALUE
PROPOSITIONTECHNOLOGIES
• Founded in 2013 in Taipei City, Health2Sync provides a Chronic Disease
Management Solution, starting with Diabetes.
• Using the Health2Sync app, Health2Sync builds a personalized care
service based on the blood glucose values and daily activities you have
recorded. User can also link to the care team, family and friends and
have them serve as their glucose control partners. Based on patterns,
the app gives you reminders and tips based on your records, to assist you
in making timely adjustments.
Health2Sync
DESCRIPTION
• Health2Sync revolutionizes diabetes care through personalization &
analytics. We enable care to scale and collaboration for parties in the
ecosystem.
• The Health2Sync system (mobile app, web app, analytics engine) is
clinically proven to help Diabetics better control blood sugar and reduce
risk of complications. We are the largest diabetes platform in Asia (ex-
China) when considering the total number of patients and hospitals /
clinics on a single network.
PRODUCT DESCRIPTION
INVESTMENT HISTORY
HEALTHTECH CATEGORISATION & CLASSIFICATION
TAIPEI, TAIWAN
MANAGEMENT
HEALTHTECH ALPHA ASSESSMENT
RELATIONSHIPSDIGITAL THERAPEUTICS
• Biosensors
• Machine Learning / Deep Learning
• Mobile Application
Date Investors Stage Amount
11 / 2017 Sompo Holdings, Alibaba Series B US$ 6
08 / 2016 Alibaba, WI Harper Series A US$ 3
06 / 2014 Cherubic Ventures Seed US$ 1
Name / Title Background
Ed Deng
(Co-Founder &
CEO)
• Prior Chief Marketing Officer of Hesine Technologies
acquired by Link Motion
• Co-founded Merchantrun, an e-commerce software
provider that was acquired by 4PX.
• Investment Banker at Lehman Brothers’s Technology
Mergers & Acquisitions Group in Palo Alto, CA.
• BS in Finance from McIntire School of Commerce at The
University of Virginia.
+20 20
+13
+20 24
-20
0
20
40
Alpha
M
om
entum
M
arket
Im
pact
M
oney
Alpha Indices relative to the average value for each index in Taiwan

11. ©2019 by Galen Growth Asia - All rights reserved.
11
DTX WEBINAR ONLY | NOT FOR DISTRIBUTION
ABOUT
GALEN GROWTH ASIA

12. ©2019 by Galen Growth Asia - All rights reserved.
12
DTX WEBINAR ONLY | NOT FOR DISTRIBUTION
Founded in late 2015 by Singapore based HealthTech innovators, Galen
Growth Asia (GGA), is at the epicentre of digital health innovation
currently a $75+B startup ecosystem
GGA has built a portfolio of solutions which enables it to be the catalyst
of direct collaboration between enterprises, startups and investors to
prototype, evaluate and implement HealthTech solutions to solve
healthcare system pain points and create significant financial and social
value in the region
We partner with enterprise, investors and startups to accelerate and
deepen their understanding of this exciting ecosystem. We offer client
specific analytics and advisory solutions to help them find the right
options and scale their innovation plans
Galen Growth Asia, a Singapore company, is the leading research, analytics and advisory firm in Asia Pac serving Fortune
500 companies and global investors, exclusively HealthTech focused
We Fast Track HealthTech Strategies
Accelerate Strategies
By leveraging its thought leadership, research, data and unique ecosystem
network, GGA is in the enviable position of assisting enterprise, investors and
startups ventures to accelerate the design and execution their HealthTech
growth strategies
Discover Solutions
GGA has built the most advance HealthTech ventures analytics platform
allowing it and its clients to scan, screen and develop valuable insights.
Through its rich network and this unique database, GGA is the leading
authority in the Asia Pacific HealthTech ecosystem
Engage Innovators
GGA has established the most comprehensive and relevant network of
HealthTech startups and innovators across the region which includes
entrepreneurs, investors, enterprise innovation teams, and many other key
stakeholder groups allowing innovators to embed within the ecosystem
faster
ABOUT GGA

13. ©2019 by Galen Growth Asia - All rights reserved.
13
DTX WEBINAR ONLY | NOT FOR DISTRIBUTION
OUR VALUE PROPOSITION
HealthTech
Acceleration
HealthTech
Alpha
Asia
HealthTech
Council
HealthTech
Tribe
Asia’s only dedicated annual HealthTech Summit: The Summit for the most innovative minds in Asia
HealthTech: Investor Day and Enterprise Day, culminating in the much coveted Most Innovative HealthTech
Startup in Asia Award.
Quarterly HealthTech Deal Flow events – connecting the ecosystem movers and shakers – by invitation only
The Moneyball of Asia HealthTech! Continuously curated and updated.
Asia HealthTech’s most advanced ecosystem analytics platform, used by investors, enterprise and startups,
giving access to unique insights on the thousands of digital health startups to make better informed decisions
The HealthTech Council propels the ambitions of innovation leaders through their peer-to-peer
collaborative and reflective practices to build and enable the future of healthcare in Asia. An enterprise-to-
enterprise Innovation Lab!
It is tailored to provide timely insights to help each member to accelerate the delivery of their digital health
strategies, make timely decisions and be recognised as innovation champion
Specialist Digital Health Advisory to Enterprise, Investors & Startups
Design: The Why&What - Accelerate the design of a client’s digital health strategy incl. alignment of internal
stakeholders
Execution: The How&Who – Construct & kick-off the strategy execution plan incl. identification of suitable
startups for potential partnership

14. ©2019 by Galen Growth Asia - All rights reserved.
14
DTX WEBINAR ONLY | NOT FOR DISTRIBUTION
FEATURED IN
Bloomberg

15. ©2019 by Galen Growth Asia - All rights reserved.
15
DTX WEBINAR ONLY | NOT FOR DISTRIBUTION
https://www.linkedin.com/company/galen-growth-asia/
https://twitter.com/galengrowthasia
https://www.galengrowth.asia
info@galengrowth.asia
THANK YOU!
Connect, Share, Like